Think Bioscience has secured $55M in an oversubscribed Series A to advance a platform that treats drug discovery as a biological survival game rather than just a computational problem. Instead of relying solely on digital simulations to find binding pockets on difficult proteins, Think “programs” microbes to generate millions of small molecules. The system is set up so that the microbe only survives if it successfully produces a molecule that inhibits a specific disease target. It is essentially forcing evolution to do the heavy lifting of medicinal chemistry.
The funding will primarily fuel their lead program targeting Noonan syndrome, a genetic disorder with no approved therapies that address its underlying biology. By leveraging synthetic biology to access “undruggable” targets (like dynamic protein pockets that static crystal structures miss), Think is carving out a niche distinct from the crowded “AI for Drug Discovery” space. This raise attracts high-profile backing from Regeneron Ventures and Innovation Endeavors, signaling strong institutional confidence in hybrid bio-computational models.